Influence of the dopamine agonist α-dihydroergocryptine on the pharmacokinetics of levodopa in patients with Parkinson's disease

Clinical Neuropharmacology

Volumn 24, Issue 4, 2001, Pages 235-238

  Minea, Dan ^a   Varga, Ioana ^a   Falup Pěcurariu, Christian ^a   De Mey, Christian ^b   Retzow, Angelika ^d   Althaus, Michael ^c  

^a University of Transsilvania   (Romania)

^b Applied Clinical Pharmacology Services   (Germany)

^c ALK SCHERAX Arzneimittel GmbH   (Germany)

^d NONE

Author keywords

Interaction; Levodopa; Parkinson's disease; Pharmacokinetics; dihydroergocryptine

Indexed keywords

CARBIDOPA PLUS LEVODOPA; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG MIXTURE; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0034894367     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200107000-00008     Document Type: Article

References (10)

1. Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: Results of a multicentre, randomized, double-blind, placebo-controlled study
2. Alpha-dihydroergocryptine in Parkinson's disease: A multicentre randomized double blind parallel group study
3. The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease
4. Lack of pharmacokinetic influence on levodopa by bromocriptine
5. No effect of chronic bromocriptine therapy on levodopa pharmacokinetics in patients with Parkinson's disease
6. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease
7. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies
8. Pharmacokinetic model of oral levodopa and role of carbidopa in parkinsonian patients
9. Dosage form design for improvement of bioavailability of levodopa. III: Influence of dose on pharmacokinetic behavior of levodopa in dogs and Parkinsonian patients
10. Therapie des morbus Parkinson mit α-dihydroergocryptin in der neurologischen praxis